VENUS REMEDIES
|
The Current P/E Ratio of VENUS REMEDIES is 13.74.
| Share Price | ₹721.4 | Jan 20,2026 |
| Market Cap | ₹966.7 Cr | |
| Earnings-TTM | ₹70.3 Cr | TTM-Consolidated Results |
| Price/Earnings | 13.74x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of VENUS REMEDIES
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹966.7 Cr] as on Jan 20,2026
(/) Earnings [ ₹70.3 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 13.74x ]
Thus, for VENUS REMEDIES , the investors are currently willing to pay 13.74 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of VENUS REMEDIES !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of VENUS REMEDIES over the last five years.
Historical PE (Price/Earnings) ratio chart of VENUS REMEDIES
PE Ratio Performance Analysis for VENUS REMEDIES
- VENUS REMEDIES 's p/e ratio for fiscal years ending Mar2025 to Mar2021 averaged 9.32x.
- VENUS REMEDIES 's operated at median p/e ratio of 8.82x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, VENUS REMEDIES 's p/e ratio peaked in Mar2024 at 15.31x.
- VENUS REMEDIES 's p/e ratio hit its five-year low in Mar2021 of 5.49x.
How does VENUS REMEDIES 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| VENUS REMEDIES | 70.33 | 13.74 | 966.7 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 10,517.90 | 36.77 | 386,773.0 |
| DIVIS LABORATORIES LTD | 2,485.00 | 64.20 | 159,540.0 |
| CIPLA LTD | 5,453.86 | 20.41 | 111,299.0 |
| TORRENT PHARMACEUTICALS LTD | 2,140.00 | 62.86 | 134,529.0 |
| DR REDDYS LABORATORIES LTD | 5,721.40 | 17.02 | 97,393.0 |
| MANKIND PHARMA LTD | 1,767.06 | 49.62 | 87,675.7 |
| ZYDUS LIFESCIENCES LTD | 4,973.40 | 17.66 | 87,839.2 |
| LUPIN LTD | 4,347.53 | 22.76 | 98,947.2 |
| AUROBINDO PHARMA LTD | 3,447.75 | 19.21 | 66,228.8 |
| ABBOTT INDIA LTD | 1,508.95 | 38.33 | 57,831.0 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs VENUS REMEDIES 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | 13.74x |
| Max industry PE | 64.20x |
| Median industry PE | 22.76x |
| Average industry PE | 32.96x |
You may also like the below Video Courses